1. Scrip
  2. >>Focus On Asia
  3. >>Japan

MSD To Launch Rotavirus Vaccine Rotateq In Japan

Merck & Co. subsidiary Merck Sharp & Dohme Ltd. announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20.

Merck & Co. subsidiaryMerck Sharp & Dohme Ltd.announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20. Most children who suffer from the rotavirus are infected by the illness by the age of 5, experiencing diarrhea, vomiting, and fever, but complications can also lead to dehydration, cramps, and even encephalitis. Currently, only symptomatic treatment exists for the illness, but MSD aims to spread prevention through vaccination. Rotavirus has many serotypes, but 90% of cases are caused by G1P(8), G2P(4), G3P(8), G4P(8), or (G9P(8). The vaccine targets these serotypes with a 100% efficacy against severe rotavirus gastroenteritis. (Click Here For More – Japanese Language)

“MSD: Rotavirus Vaccine Rotateq On Sale From July 20” mixonline.jp 7/12/2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Focus On Asia

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.